Press Releases
Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference    1667 2500 Eyevensys

Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference   

Paris, France, and Cambridge, Mass., United States, May 11, 2022 — Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the…

Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting 2500 1667 Eyevensys

Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its…

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical 1920 1080 Eyevensys

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Manufacturing of Eyevensys’ core ocular device and electrical pulse generator technology covered under a new collaboration

Eyevensys Raises $12M in a Series B Plus Funding Round 1920 1277 Eyevensys

Eyevensys Raises $12M in a Series B Plus Funding Round

Paris, France, and Cambridge, Mass., United States, August 04, 2021 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies..

Eyevensys Named to French Tech 120 Program 1920 1281 Eyevensys

Eyevensys Named to French Tech 120 Program

Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…

Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa 1920 1080 Eyevensys

Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa

Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company..

Eyevensys Announces Executive Leadership Team Expansion 1920 1277 Eyevensys

Eyevensys Announces Executive Leadership Team Expansion

Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Paris, France, and Fort Worth, Texas, United…

Eyevensys Closes $30M Series B Financing 1920 1281 Eyevensys

Eyevensys Closes $30M Series B Financing

Eyevensys announced today that it has completed a $30 million Series B financing. The round was led by Boehringer Ingelheim Venture Fund and included participation from existing investors Pontifax, Bpifrance,…

Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases 1920 1281 Eyevensys

Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases

Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual [email protected] conference on October 10,…

Eyevensys Appoints New Board Member, Gerald Cagle 1920 1280 Eyevensys

Eyevensys Appoints New Board Member, Gerald Cagle

Eyevensys today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board  of Directors. Dr. Cagle is a highly…

  • 1
  • 2
Load More
Start Typing